Protein kinase C: A worthwhile target for anticancer drugs?

Anti-Cancer Drugs

Volumn 8, Issue 1, 1997, Pages 26-33

  Caponigro, Francesco ^a,b   French, Raymond C ^a   Kaye, Stan B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

drug resistance; protein kinase C; tumor growth

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CALPHOSTIN C; DOXORUBICIN; GLYCOPROTEIN P; ISOENZYME; MIDOSTAURIN; PROTEIN KINASE C; SAFINGOL; SPHINGOSINE; STAUROSPORINE DERIVATIVE; SURAMIN; TAMOXIFEN;

CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG TARGETING; GROWTH INHIBITION; HUMAN; MULTIDRUG RESISTANCE; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PROTEIN KINASE C;

EID: 0031058595     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199701000-00003     Document Type: Review

References (70)

1. Powis G. Anticancer drugs acting against signaling pathways. Curr Opin Oncol 1995; 7: 554-9.
2. Powis G, Workman P. Signalling targets for the development of cancer drugs. Anticancer Drug Des 1994; 9: 263-77.
3. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984; 308: 693-8.
4. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-5.
5. Dekker LV, Parker PJ. Protein kinase C - a question of specificity. Trends Biochem Sci 1994; 19: 73-7.
6. Parker PJ, Kour G, Marais RM, et al. Protein kinase C - a family affair. Mol Cell Endocrinol 1989; 65: 1-11.
7. Stabel S, Parker PJ, Protein kinase C. Pharmac Ther 1991; 51: 71-95.
8. Kishimoto A, Takay Y, Mori T, et al. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980; 255: 2273-6.
9. Castagna M, Takai Y, Kaibuchi K, et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-51.
10. Niedel JE, Kuhn IJ, Vandenbark GR. Phorbol diester receptor copurifies with protein kinase C. Proc Natl Acad Sci USA 1983; 80: 36-40.
11. Takenaga K, Takahashi K. Effects of 12-O-tetradecanoylphorbol-13-acetate on adhesiveness and lung-colonizing ability of Lewis lung carcinoma cells. Cancer Res 1986; 46: 375-80.
12. Gopalakrishna R, Barsky SH. Tumor promoter-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci USA 1988; 85: 612-6.
13. ++ mobilization and protein kinase C activation in the induction of spontaneous metastasis by mouse mammary adenocarcinoma cells. Cancer Res 1989; 49: 2597-602.
14. Isakov N, Gopas J, Priel E, et al. Effect of protein kinase C activating tumor promoters on metastases formation by fibrosarcoma cells. Invasion Metastasis 1991; 11: 14-24.
15. Schwartz GK, Redwood SM, Ohnuma T, et al. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C, inhibitor staurosporine. J Natl Cancer Inst 1990; 82: 1753-6.
16. Schwartz GK, Jiang K, Kelsen D, et al. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 1993; 85: 402-7.
17. Herbert JM. Protein kinase C: a key factor in the regulation of tumor cell adhesion to the endothelium. Biochem Pharmacol 1993; 45: 527-37.
18. Lane TA, Lamkin GE, Wancewicz E. Modulation of endothelial cell expression of intracellular adhesion molecule 1 by protein kinase C activation. Biochem Biophys Res Commun 1989; 161: 945-52.
19. O'Brian CA, Vogel VG, Singletary E, et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49: 3215-7.
20. Fabbro D, Kung W, Roos W, et al. Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship. Cancer Res 1986; 46: 2720-5.
21. Hatada T, Sakanoue Y, Kusunoki M, et al. Protein kinase C activity in human thyroid carcinoma and adenoma. Cancer 1992; 70: 2918-22.
22. Couldwell WT, Hinton DR, Surnock AA, et al. Treat ment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-22.
23. Kopp R, Noelke B, Sauter G, et al. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 1991; 51: 205-10.
24. Becker D, Beebe SJ, Herlyn M. Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas. Oncogene 1990; 5: 1133-9.
25. Yamanishi DT, Graham M, Buckmeier JA, et al. The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis 1991; 12: 105-9.
26. Schaufelberger DE, Koleck MP, Beutler JA, et al. The large-scale isolation of bryostatin 1 from Bugula nerutina following current good manufacturing practices. J Nat Prod 1991; 54: 1265-70.
27. Dale IL, Gescher A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells, Int J Cancer 1989; 43: 158-63.
28. Hornung RL, Pearson JW, Beckwith M, et al. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1991; 52: 101-7.
29. Schuchter LM, Esa AH, May S, et al. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991; 51: 682-7.
30. 3H}bryostatin 4 to protein kinase C. Biochem Pharmacol 1992; 43: 2007-14.
31. Mohr H, Pettit GR, Plessing-Menze A. Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 1987; 175: 425-30.
32. Trenn G, Pettit GR, Takayama H, et al. Immunomodulating properties of a novel series of protein kinase C activators. The biostatins. J Immunol 1988; 140: 433-9.
33. O'Brian CA, Housey GM, Weinstein IB. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 1988; 48: 3626-9.
34. Edashige K, Sato EF, Akimaru K, et al. Nonsteroidal antiestrogen suppresses protein kinase C: its inhibitory effect on interaction of substrate protein with membrane. Cell Struct Funct 1991; 16: 273-81.
35. Wiebe VJ, Osborne CK, Fuqua SAW, et al. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993; 14: 173-88.
36. Fabbro D, Regazzi R, Costa SD, et al. Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells. Biochem Biophys Res Commun 1986; 135: 65-73.
37. O'Brian CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462-5.
38. Mahoney CW, Azzi A, Huang KP. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C: differential activation and inhibition of protein kinase C. isozymes. J Biol Chem 1990; 265: 5424-8.
39. ++ dependent protein kinase. Biochem Biophys Res Commun 1986; 135: 397-402.
40. Tamaoki T, Nakano H. Potent and specific inhibitors of protein kinase C. of microbial origin. Biotechnology 1990; 8: 732-5.
41. Takahashi I, Koboyashi E, Asana K, et al. UCN-01, a selective inhibitor of protein kinase C from streptomices. J Antibiot 1987; 40: 1782-4.
42. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporin (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int J Cancer 1989; 43: 851-6.
43. Van Der Bliek A, Borst P. Multidrug resistance. Adv Cancer Res 1989; 52: 165-203.
44. Tsurou T, Iida H, Kawabata H, et al. High calcium content of pleiotropic drug-resistant P388 and K562 leukemia and Chinese hamster ovary cells. Cancer Res 1984; 44: 5095-9.
45. Fine R, Patel J, Chabner B. Phorbol esters induce MDR in human breast cancer cells. Proc Natl Acad Sci USA 1988; 85: 582-6.
46. Efferth T, Volm M. Expression of protein kinase C in human renal cell carcinoma cells with inherent resistance to doxorubicin. Anticancer Res 1992; 12: 2209-12.
47. Volm M, Pommerenke EW. Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res 1995; 15: 463-6.
48. Dong Z, Ward N, Fan D, et al. In vitro model for intrinsic drug resistance: effects of PKC activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 1991; 39: 563-9.
49. Posada J, McKeegan E, Worthington K, et al. Human multidrug resistant KB cells overexpress PKC: involvement in drug resistance. Cancer Commun 1989; 1: 285-92.
50. Chambers TC, Zheng B, Kuo JF. Regulation by phorbol esters and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 1992; 41: 1008-15.
51. Ido M, Sakurai M, Inagaki M, et al. An inhibitor of protein kinase C 1-(5-isoquinolinylsulfonyl)-2-methypiperazine (H-7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemia cell. Leak Res 1986; 10: 1063-9.
52. Utz I, Hofer S, Regenass U, et al. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance, Int J Cancer 1994; 57: 104-10.
53. Budworth J, Davies R, Malkhandi J, et al. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 1996; 73: 1063-8.
54. Blobe GC, Sachs CW, Khan WA, et al. Selective regulation of expression of protein kinase C. (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC-alpha. J Biol Chem 1993; 268: 658-64.
55. Yu G, Ahmad S, Aquino A, et al. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 1991; 3: 181-9.
56. O'Brian C, Fan D, Ward N, et al. Transient enhancement of MDR by the bile acid deozycholate in murine fibrosarcoma cells in vitro. Biochem Pharmacol 1991; 41: 797-806.
57. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Met Rev 1994; 13: 411-31.
58. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-9.
59. Susick RL, Bozigian HP, Kurtberg J, et al. Combination toxicology studies with the chemopotentiating agent SPC-100270 (a PKC inhibitor) and chemotherapeutic agents. Proc Am Ass Cancer Res 1993; 34: 410.
60. Adams LM, Dykes D, Harrison SD, et al. Combined effect of the chemopotentiator SPC-100270. a protein kinase C (PKC) inhibitor, and doxorubicin (dox) or cisplatin (cis) on murine isografts and human tumor xenografts. Proc Am Ass Cancer Res 1993; 34: 410.
61. Evans DI, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53: 2133-9.
62. Jarvis WD, Turner AJ, Povirk LE, et al. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocitic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 1994; 54: 1707-14.
63. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, et al. Potentiation of apoptosis by treatment with the protein kinase C specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 1995; 87: 1394-9.
64. Prendiville J, Crowter D, Thatcher N, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418-24.
65. Philip PA, Rea D, Thavasu P, et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J Natl Cancer Inst 1993; 85: 1812-8.
66. Jayson GC, Crowter D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995; 72: 461-8.
67. Schwartz GK, Ward D, Saltz L, et al. A phase 1 study of the protein kinase C (PKC) specific inhibitor safingol (Saf) alone and in combination with doxorubicin (Dox). Proc Am Soc Clin Oncol 1995; 14: 479.
68. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-24.
69. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother Pharmacol 1986; 18: 239-42.
70. Lum BL, Kaubish S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.